Companies /Healthcare

Cassava Sciences Inc

NASDAQ: SAVA Biotechnology
$2.38
▲ $0.00 (+0.00%) today
Markets closed · 5:55am ET

SAVA at a Glance

Valuation
Market cap
$115.0M
Profitability
EPS (TTM)
$-2.22
Price
52-week range
$1 – $3
Street target
$8.00

Headquartered in Austin, TX Fiscal year ends December NASDAQ: SAVA cassavasciences.com

About Cassava Sciences

Filana Therapeutics, Inc. (NASDAQ: FLNA) is a clinical-stage biotechnology company developing investigational therapies that modulate the filamin A protein. It targets central nervous system disorders and other diseases associated with dysregulation or overexpression of filamin A. Its lead candidate, simufilam, is an oral small molecule being advanced for Tuberous Sclerosis Complex (TSC)-related epilepsy, a rare genetic seizure disorder linked to TSC1/TSC2 mutations and the mTOR pathway. The disorder affects an estimated 45,000 people in the U.S. In September 2026 the FDA lifted a clinical hold on the simufilam IND for this indication. The company is now preparing a roughly 40-patient, randomized, double-blind Phase 2a study at about 13 U.S. sites, with patient screening expected by Q1 2027. Filana has no approved products and generates no revenue. It funds operations from its cash balance, has no debt, and has placed funds in escrow related to a potential settlement of securities litigation. Updated

SAVA Coverage

Frequently Asked Questions

What does Cassava Sciences do?

Filana Therapeutics, Inc. (NASDAQ: FLNA) is a clinical-stage biotechnology company developing investigational therapies that modulate the filamin A protein. It targets central nervous system disorders and other diseases associated with dysregulation or overexpression of filamin A.

What is the SAVA stock price target?

The Wall Street consensus 12-month price target for SAVA is $8.00.